VISCOSUPPLEMENTATION MARKET ANALYSIS

Viscosupplementation Market, By Dosage (Single Injection, Three Injection, and Five Injection), By Arthritis Type (Osteoarthritis and Rheumatoid Arthritis), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In September 2021, Bioventus Inc., a frontrunner in advancements for active healing, revealed that the American Academy of Orthopaedic Surgeons (AAOS) has issued revised clinical practice guidelines (CPG), highlighting that high molecular weight cross-linked hyaluronic therapies, such as Bioventus' DUROLANE, have demonstrated statistically notable enhancements in specific knee osteoarthritis (OA) cases.
In August 2021, Seikagaku Corporation, a pharmaceutical company introduced HyLink, a single-injection viscosupplement designed for intra-articular treatment of knee osteoarthritis in Taiwan, in partnership with TCM Biotech International Corp., a biotechnology company. HyLink features a cross-linked hyaluronate hydrogel, crafted utilizing Seikagaku Corporation's distinctive crosslinking method, as its primary component.